HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

Chinese retail strategy includes opening 1,000 beauty boutiques in 2001 to achieve points-of-sale in every major Chinese city, direct-seller says. Effort is reaction to Chinese government's 1998 ban on direct selling, which required Avon to redevelop its business, resulting in current operation of 2,500 retail stores. Avon expects sales in China to double to more than $150 mil. by 2003. Sales in region were up 44% to $71 mil. in 2000, comparable to company's selling levels before the ban, Avon says. Firm is launching Anew Retroactive anti-aging skin care product in China

You may also be interested in...



Avon Redesigned Brochure Slated For U.S. Launch In September

Avon will introduce a new customer brochure in September designed to be "consistent" with the firm's beauty image and advertising pitch, Group VP Bob Briddon said during an investor update meeting in New York City May 8.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel